Related Experiment Video

Updated: Jul 8, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Pharmacogenomics: a tool to prevent and cure coronary heart disease

Giuseppina Candore1, Carmela Rita Balistreri, Marco Caruso

  • 1Dipartimento di Biopatologia e Metodologie, Malattie Cardiovascolari e Nefrourologiche, Università di Palermo, Italy. gcandore@unipa.it

Current Pharmaceutical Design
|January 29, 2008
PubMed

Insights

Genetic variations in inflammatory genes like IL-6 and TLR4 are linked to coronary heart disease (CHD) and myocardial infarction (MI) risk. Screening these gene polymorphisms can improve risk assessment and identify potential therapeutic targets.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Medicine
  • Immunology

Background:

  • Coronary heart disease (CHD) and myocardial infarction (MI) pathogenesis involve inflammation and genetic factors.
  • Epidemiological studies highlight associations between CHD and polymorphisms in inflammatory molecules.
  • Current therapeutic strategies for CHD/MI remain limited, and pharmacogenomic approaches are underexplored.

Purpose of the Study:

  • To identify key inflammatory genes and their polymorphisms associated with CHD and MI risk.
  • To evaluate the utility of screening specific gene polymorphisms for CHD/MI risk assessment.
  • To explore the potential of genetic profiling in identifying susceptible individuals and novel drug targets.

Main Methods:

  • Literature review focusing on inflammatory genes and their association with CHD/MI.
  • Identification of candidate genes including pro- and anti-inflammatory cytokines, Toll-like receptor 4 (TLR4), CD14, CCR5, cyclooxygenases (COXs), and lipoxygenases (LOXs).
  • Analysis of the complexity of gene-disease associations, considering factors like pleiotropy, age, lethality, and gene-environment interactions.

Main Results:

  • Several inflammatory genes, such as interleukin (IL)-6, IL-10, TLR4, CCR5, COX, and LOX, are implicated in CHD and MI risk.
  • Screening for polymorphisms in these genes shows potential as a valuable tool for CHD and MI risk assessment.
  • The interplay of genetic polymorphisms with other factors complicates but underscores the importance of genetic assessment.

Conclusions:

  • Genetic polymorphisms in key inflammatory pathways significantly contribute to CHD and MI risk.
  • Screening for specific gene polymorphisms (IL-6, IL-10, TLR4, CCR5, COX, LOX) can enhance cardiovascular risk assessment.
  • Understanding genetic influences can lead to early identification of at-risk individuals and inform the development of targeted therapies and lifestyle modifications.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...